Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.
Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).
Lu
M Janice
MJ
New York University Cancer Institute, School of Medicine, New York, NY 10016, USA.
Sorich
Joan
J
Hazarika
Maitreyee
M
Kim
Mimi
M
Del Priore
Giuseppe
G
Jacobs
Allan J
AJ
Chiang
Chang
C
Liu
Paul C
PC
Fusco
Eileen
E
Curtin
John P
JP
Muggia
Franco M
FM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
D005467:Floxuridine; D016190:Carboplatin; D002945:Cisplatin